Mice lacking the lectin-like domain of thrombomodulin are protected against melioidosis

Critical Care Medicine

Volumn 42, Issue 3, 2014, Pages

  Kager, Liesbeth M ^a   Wiersinga, W Joost ^a   Roelofs, Joris J T H ^a   Stroo, Ingrid ^a,b   Achouiti, Ahmed ^a   Van 'T Veer, Cornelis ^a   Conway, Edward M ^c   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

coagulation; inflammation; melioidosis; pneumonia; sepsis; thrombomodulin

Indexed keywords

ANIMALS; BACTERIAL LOAD; BIOPSY, NEEDLE; BRONCHOALVEOLAR LAVAGE FLUID; BURKHOLDERIA PSEUDOMALLEI; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LECTINS; LUNG; MALE; MELIOIDOSIS; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THROMBOMODULIN;

EID: 84894459534     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000134     Document Type: Article

References (38)

1. Esmon CT: The protein C pathway. Chest 2003; 124:26S-32S
2. Conway EM: Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34:107-125
3. Levi M, Van Der Poll T: Thrombomodulin in sepsis. Minerva Anestesiol 2013; 79:294-298
4. Myles T, Nishimura T, Yun TH, et al: Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278:51059-51067
5. Delvaeye M, Noris M, De Vriese A, et al: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345-357
6. Van de Wouwer M, Plaisance S, de Vriese A, et al: The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4:1813-1824
7. Shi CS, Shi GY, Hsiao HM, et al: Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008; 112:3661-3670
8. Kuo CH, Chen PK, Chang BI, et al: The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood 2012; 119:1302-1313
9. Abeyama K, Stern DM, Ito Y, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115:1267-1274
10. Weiler-Guettler H, Christie PD, Beeler DL, et al: A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101:1983-1991
11. Conway EM, Van de Wouwer M, Pollefeyt S, et al: The lectin-like domain of thrombomodulin confers protection from neutrophil- mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196:565-577
12. Huang HC, Shi GY, Jiang SJ, et al: Thrombomodulin-mediated cell adhesion: Involvement of its lectin-like domain. J Biol Chem 2003; 278:46750-46759
13. Geudens N, Van de Wouwer M, Vanaudenaerde BM, et al: The lectin- like domain of thrombomodulin protects against ischaemia- reperfusion lung injury. Eur Respir J 2008; 32:862-870
14. Zoja C, Locatelli M, Pagani C, et al: Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol 2012; 189:3661-3668
15. Wang H, Vinnikov I, Shahzad K, et al: The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. Thromb Haemost 2012; 108:1141-1153
16. Takagi T, Taguchi O, Toda M, et al: Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2011; 183:31-42
17. Schouten M, de Boer JD, van t Veer C, et al: The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia. Eur Respir J 2013; 41:935-942
18. Currie BJ, Ward L, Cheng AC: The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:e900
19. Wiersinga WJ, Currie BJ, Peacock SJ: Melioidosis. N Engl J Med 2012; 367:1035-1044
20. Wiersinga WJ, van der Poll T, White NJ, et al: Melioidosis: Insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4:272-282
21. Butler D: Viral research faces clampdown. Nature 2012; 490:456
22. Wiersinga WJ, Meijers JC, Levi M, et al: Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6:32-39
23. Kager LM, Wiersinga WJ, Roelofs JJ, et al: Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). J Thromb Haemost 2013; 11:282-292
24. Kager LM, Wiersinga WJ, Roelofs JJ, et al: Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). J Thromb Haemost 2011; 9:2020-2028
25. Kager LM, Wiersinga WJ, Roelofs JJ, et al: Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis). Crit Care Med 2012; 40:2168-2175
26. Wiersinga WJ, Wieland CW, Dessing MC, et al: Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med 2007; 4:e248
27. Easton A, Haque A, Chu K, et al: A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007; 195:99-107
28. Mizgerd JP: Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-727
29. Van de Wouwer M, Conway EM: Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32:S254-S261
30. Beutler B, Rietschel ET: Innate immune sensing and its roots: The story of endotoxin. Nat Rev Immunol 2003; 3:169-176
31. Andersson U, Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29:139-162
32. Schmidt AM, Yan SD, Yan SF, et al: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955
33. Yang H, Hreggvidsdottir HS, Palmblad K, et al: A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010; 107:11942-11947
34. Zetterstrm CK, Bergman T, Rynnel-Dag B, et al: High mobility group box chromosomal protein 1 (HMGB1) is an antibacterial factor produced by the human adenoid. Pediatr Res 2002; 52:148-154
35. Walport MJ: Complement. First of two parts. N Engl J Med 2001; 344:1058-1066
36. Egan AM, Gordon DL: Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 1996; 64:4952-4959
37. Yamakawa K, Fujimi S, Mohri T, et al: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit Care 2011; 15:R123
38. Ogawa Y, Yamakawa K, Ogura H, et al: Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012; 72:1150-1157